Live attenuated viral vaccine antigen-immune response interaction (LAV-Immune Interaction)

Live attenuated viral vaccines (LAVs) represent a class of immunizations that utilize a weakened version of a pathogenic virus to stimulate a protective immune response. Unlike inactivated vaccines, LAVs undergo limited replication within the host, which allows them to closely mimic a natural infection and provide comprehensive, often lifelong, immunity through both B-cell and T-cell activation (HHS, 2023). This interaction involves the recognition of viral antigens by pattern recognition receptors, followed by antigen processing and presentation to the adaptive immune system via MHC class I and II molecules (StatPearls, 2023). While highly effective, the use of LAVs requires careful consideration of the host's immune status, as the replicating virus can cause opportunistic infections in immunocompromised individuals (CDC, 2021). Additionally, there is a minimal but documented risk of the attenuated virus undergoing genetic mutations that restore its original virulence, a process known as reversion (PubMed, PMC4205388).

Other names

Live attenuated vaccine interactionLAV-induced immunityAttenuated virus-host interactionVaccine-antigen immune response

Live attenuated vaccines work by mimicking a natural infection. The weakened virus replicates in the host, presenting a broad array of antigens to the immune system, which induces robust, long-term humoral (antibody) and cellular (T-cell) memory without causing the full-blown disease (StatPearls, 2023).